Remove 2030 Remove Pharmaceuticals Remove Regulations
article thumbnail

Analysis Chemical Thank You California publishes draft regulations for landmark plastic pollution reduction act

Agency IQ

California publishes draft regulations for landmark plastic pollution reduction act CalRecycle has launched the formal rulemaking process for Senate Bill 54, which will implement a sweeping plan to reduce plastic waste in the state by 2032. That amount will increase to 40% in 2030 and 65% in 2032.

article thumbnail

Six Factors for Biotech Companies to Consider When Choosing Next-Generation Contract GMP/CMC Laboratories

PPD

There has been an unprecedented expansion of different types of pharmaceutical therapies, as well as a change in the overall approach to health care. Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Race for Ozempic Alternatives: Unlocking the Future of Weight Loss Medication

DrugBank

Pharmaceutical researchers, in particular, have a keen interest in understanding the unfolding dynamics of this market. adults using obesity medications by 2030, further underlining the growing significance of this sector. Let’s delve into what lies ahead in the coming year.

article thumbnail

Regulatory Developments in Ophthalmology: Applying New FDA Guidance, Part One

The Premier Consulting Blog

billion in 2022 and is expected to grow approximately eight percent from 2023 to 2030 [1]. The FDA has determined that ophthalmic dispensers are now regulated as devices, and the drug and device together are regulated as a combination product. The global ophthalmic drugs market size was valued at $33.81

FDA 52
article thumbnail

Shaping the Future: Eli Lilly's Role in the Weight Management Revolution

DrugBank

billion in 2022 and is projected to grow at a compound annual growth rate of 9.94% from 2023 to 2030. Eli Lilly's Triumph: Pioneering Solutions in Weight Management Eli Lilly's remarkable achievement with its drug Mounjaro (tirzepatide) in the fourth quarter of 2023 has sent ripples of excitement through the pharmaceutical industry.

article thumbnail

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research

Vial

Within each of these, pharmaceutical and biotech sponsors are supported by preclinical and clinical contract research organizations (CROs) in clinical trials across various indications. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. What is a Pre-Clinical CRO? over this period.

article thumbnail

Why Do Pharma Companies Outsource to CROs?

Vial

Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. over the forecast period (2022-2030). Their ability to adapt to evolving regulations and industry standards reduces the likelihood of costly setbacks.